Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Atossa Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ATOS: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders7359−14
Shares23.3M19.0M−4.25M (−18.3%)
Value$25.4M$15.8M−$9.55M (−37.6%)

New holders (7)

Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ATOS in Q3 2022
InstitutionSharesValue% of portfolio
Mariner, LLC104,861$87.0K0.00%
Gsa Capital Partners LLP71,901$60.0K0.01%
Susquehanna Fundamental Investments, LLC34,788$29.0K0.00%
Group One Trading, L.P.22,141$18.0K0.00%
Abound Wealth Management6$50.00%
The PNC Financial Services Group, Inc.6$00.00%
Bogart Wealth, LLC500$00.00%

Sold out (21)

Institutions that held Atossa Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.